Chartwell Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Chartwell Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,672	Closed	-$447K	–	417
2022 Q3	$447K	Buy	46,672 +1,635	+4%	+$18.9K	0.02%	390
2022 Q2	$497K	Buy	+45,037	New	+$590K	0.02%	395
2021 Q4	–	Sell	-60,750	Closed	-$1.5M	–	434
2021 Q3	$1.5M	Buy	60,750 +12,326	+25%	+$290K	0.05%	335
2021 Q2	$1.26M	Buy	+48,424	New	+$1.26M	0.04%	354
2020 Q4	–	Sell	-32,633	Closed	-$1.07M	–	437
2020 Q3	$1.07M	Hold	32,633	–	–	0.04%	341
2020 Q2	$896K	Sell	32,633 -34,664	-52%	-$1.14M	0.03%	341
2020 Q1	$2.02M	Buy	67,297 +7,268	+12%	+$193K	0.09%	248
2019 Q4	$1.66M	Sell	60,029 -23,076	-28%	-$525K	0.05%	308
2019 Q3	$1.51M	Sell	83,105 -52,396	-39%	-$1.16M	0.05%	341
2019 Q2	$3.32M	Buy	+135,501	New	+$2.04M	0.11%	261

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Chartwell Investment Partners's IOVA Position: Q4 2022 in Review

Chartwell Investment Partners sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 46,672 shares — an estimated $447K sold.

Chartwell Investment Partners first reported a position in IOVA in Q2 2019 and held it in 10 quarters. The position peaked at $3.32M in Q2 2019. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Chartwell Investment Partners reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Chartwell Investment Partners sold 46,672 Iovance Biotherapeutics shares in Q4 2022, an estimated $447K.
Chartwell Investment Partners first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 10 quarters.
Chartwell Investment Partners's Iovance Biotherapeutics position peaked at $3.32M in Q2 2019.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Chartwell Investment Partners's 13F filing for Q4 2022, filed 16 Feb 2023.